Lpath to Conduct In Vivo Studies in Diabetic Neuropathy With LpathomabTM, Its Monoclonal Antibody Against Lysophosphatidic Acid (LPA)
Dallas, Texas (August 16, 2011) – StockGuru Shines its Spotlight on Lpath, Inc. (OTCBB: LPTN), the industry leader in lipidomics-based therapeutics, announced yesterday the Type 1 Diabetes Preclinical Testing Program of the National Institutes of Health (NIH) will provide financial support for the further study of Lpathomab’s efficacy in animal models of disease, particularly diabetic neuropathy. The Company closed on August 15, 2011, at $0.96, up 5.49% and in a fifty-two week range of $1.55 – 0.461.
“Bristol Myers Squibb’s recent $325 million acquisition of Amira, whose lead program is an LPA-receptor antagonist with Phase 1 results, underscores the potential value of a compound that neutralizes the LPA signaling pathway,” said Lpath’s CEO Scott Pancoast. “With assistance from the NIH for neuropathic pain and from various partners/collaborators for other central-nervous-system disorders and for fibrosis, we believe we can generate compelling data that validates Lpath’s unique approach to neutralizing LPA with Lpathomab.”
As a monoclonal antibody, Lpathomab functions like a ‘molecular sponge’ that binds to and neutralizes the bioactive lipid signaling molecule, lysophosphatidic acid (LPA), thus silencing LPA receptors associated with the transmission of pain through the nervous system. Lpathomab was generated using Lpath’s proprietary ImmuneY2™ technology.
In collaboration with researchers at the University of California, San Diego (UCSD), Lpath has generated impressive data — and reproduced those results — in a well-recognized animal model of diabetes in which significant pain relief was observed in diabetic rats after Lpathomab treatment.
NIH’s Division of Diabetes, Endocrinology & Metabolic Diseases (NIDDK) granted this new award, which will provide NIH contract resources to conduct in vivo studies in diabetic neuropathy where diabetic rats will be treated with Lpathomab. Diabetic peripheral neuropathy (DPN) is the most common long-term complication of diabetes mellitus and is experienced by the majority of patients. Among those with either type I or type II diabetes, about 50% experience DPN. Patients with DPN often experience debilitating pain symptoms that affect day-to-day functioning and quality of life. In addition, many patients with DPN-related pain do not respond adequately to any treatment option currently available; thus there is a strong unmet need to develop new, more efficacious drugs.
According to Roger Sabbadini, Lpath’s chief scientific officer: “NIDDK’s commitment to our development of this novel anti-LPA antibody in diabetic pain reflects the potential of this drug to meet this significant unmet need. These studies could lead eventually to a therapeutic agent that would alleviate pain and suffering that afflicts millions of diabetic patients.”
About Lpathomab and Lpath’s proprietary ImmuneY2™ technology
Lpathomab was generated using Lpath’s proprietary ImmuneY2™ technology. This drug-discovery engine provides Lpath with a platform from which to generate antibodies against bioactive lipids, opening up an entire new array of drug-discovery possibilities. About 1,000 bioactive members of the lipidome are believed to exist, but the number could be considerably larger as the study of lipidomics continues to expand. Nature Reviews stated that bioactive lipids promise to occupy center-stage in cell-biology research in the twenty first century.
It is important to note that no other company or research institution has demonstrated a similar capability to generate monoclonal antibodies against lipids and that Lpath has intellectual property surrounding the technology.
About Lpath
San Diego-based Lpath, a therapeutic antibody company, is the category leader in lipidomics-based therapeutics, an emerging field of medicine that targets bioactive signaling lipids for treating a wide range of human disease. Lpath’s ImmuneY2™ drug-discovery engine has the unique ability to generate therapeutic antibodies that bind to and inhibit bioactive lipids that contribute to disease. The company has developed three drug candidates, two of which — iSONEP™ for wet AMD and ASONEP™ for cancer — have successfully completed Phase 1 trials. Lpath entered into an agreement with Pfizer (NYSE: PFE) in 2010 that provides Pfizer an exclusive option for a worldwide license to develop and commercialize iSONEP. For more information, visit www.Lpath.com.
About Type 1 Diabetes Preclinical Testing Program (T1D-PTP)
The NIDDK recently established the T1D-PTP program to provide investigators with access to the established facilities and expertise needed to extend, enhance, and validate preclinical studies of promising new therapeutics in the diabetes arena — see www.t1diabetes.nih.gov/T1D-PTP.
About Forward-Looking Statements
The Company cautions you that the statements included in this press release that are not a description of historical facts are forward-looking statements. These include statements regarding: the eventual commercial viability of the Company’s drug programs and the eventual revenues and profitability that the Company would attain if the drug eventually gets approved. Actual results may differ materially from those set forth in this press release due to the risks and uncertainties inherent in the Company’s business, including, without limitation: the results of any future preclinical and clinical trials may not be favorable, and the Company may never receive regulatory approval for any of its drug candidates; and the Company may not be able to secure the funds necessary to support its preclinical- and clinical-development plans. More detailed information about the Company and the risk factors that may affect the realization of forward-looking statements is set forth in the Company’s filings with the Securities and Exchange Commission, including its Annual Report on Form 10-K and its Quarterly Reports on Form 10-Q filed with the SEC. Such documents may be read free of charge on the SEC’s web site at www.sec.gov. You are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and the Company undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995.
To view this StockGuru Spotlight, please visit: http://stockguru.com/category/latest-spotlights/
To get free alerts on this and other similar stocks, please register here:
What is the StockGuru Spotlight?
Many companies covered in The StockGuru Spotlight have positive increases in both volume and share price. While this is not true in all cases, StockGuru strives to cover companies in The StockGuru Spotlight that are worth of our readers’ attention.
StockGuru looks for potential break-out candidates in The StockGuru Spotlight. Many of these companies have had recent news and appear to be getting the attention of investors. StockGuru does not typically feature companies in The StockGuru Spotlight that are compensating StockGuru for this coverage. There are times when StockGuru covers a stock in The StockGuru Spotlight that had previously compensated Stockguru. Where that is the case, a proper disclosure is included below. StockGuru and its partners, employees and writers never hold shares, short positions, warrants or any other current position in a stock featured in The StockGuru Spotlight.
To feature a company in The StockGuru Spotlight please contact the Publisher at [email protected]. If our reader is a key person for a publicly traded company, StockGuru can consider that company for either a StockGuru Spotlight or a StockGuru Profile. Please contact the StockGuru Publisher John Pentony at this email address: [email protected].
Stockguru.com (“SG”) provides its members with the latest news, press releases, and trade alerts for all the companies highlighted on the site StockGuru.com. SG utilizes information believed to be reliable herein prepared all material. The information contained herein is not guaranteed by SG to be accurate, and should not be considered to be all-inclusive. The owner, publisher, editor and their associates are not responsible for errors and omissions. SG encourages readers and investors to supplement the information in these reports with independent research and other professional advice. All information on featured companies is provided by the companies profiled, or is available from public sources and SG makes no representations, warranties or guarantees as to the accuracy or completeness of the disclosure by the profiled companies or the information contained herein. The companies that are discussed in this opinion have not approved the statements made in this opinion. This opinion contains forward-looking statements that involve risks and uncertainties. This material is for informational purposes only and should not be construed as an offer or solicitation of an offer to buy or sell securities. SG is not a licensed broker, broker dealer, market maker, investment banker, investment advisor, analyst or underwriter. Please consult a broker before purchasing or selling any securities viewed on http://www.Stockguru.com or mentioned herein.
This release contains “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E the Securities Exchange Act of 1934, as amended and such forward-looking statements are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. “Forward-looking statements” describe future expectations, plans, results, or strategies and are generally preceded by words such as “may”, “future”, “plan” or “planned”, “will” or “should”, “expected”, “anticipates”, “draft”, “eventually” or “projected”. You are cautioned that such statements are subject to a multitude of risks and uncertainties that could cause future circumstances, events, or results to differ materially from those projected in the forward-looking statements, including the risks that actual results may differ materially from those projected in the forward-looking statements as a result of various factors, and other risks identified in a company’s annual report on Form 10-K or 10-KSB and other filings made by such company with the Securities and Exchange Commission. You should consider these factors in evaluating the forward-looking statements included herein, and not place undue reliance on such statements. The forward-looking statements in this release are made as of the date hereof and SG undertakes no obligation to update such statements. StockGuru is occasionally compensated for coverage. When this is the case, SG clearly indicates this with a disclosure of all compensation received in the past and present. Additionally SG also discloses any anticipated compensation in the future. Compensation is typically in cash. Sometimes a company pays SG in restricted shares. Pentony Enterprise and its associated companies does not take free trading shares for any reason at anytime. StockGuru is not a registered investment adviser or a broker-dealer. StockGuru makes no recommendation that the purchase of securities of companies profiled in this web site is suitable or advisable for any person, or that an investment in such securities will be profitable. In general, given the nature of the companies profiled and the lack of an active trading market for their securities, investing in such securities is highly speculative and carries a high degree of risk.
John Pentony, Publisher, Stockguru.com
Tel: +1 469 252 3031
e-mail: [email protected]